

Pharmaceuticals

With strengths in chiral chemistry, custom synthesis, and contract research, we manufacture APIs and intermediates for global partners. Our advanced, compliant facilities support production across scales, from grams to kilograms to tonnes, while long-standing relationships with leading pharmaceutical companies reinforce our delivery and reliability.

Human Capital

2,117
Employees

253
Personnel in R&T and technical services

Financial Capital

INR **10,210** Million
Revenue

INR **328** Million
EBIT

Who We Serve	What We Offer	Who We Partner With
Pharmaceutical companies from early-stage development till commercial launch of chemical entities.	- Contract development and manufacturing - APIs and intermediates - Food ingredients and additives	Global pharmaceutical companies looking for commercial supply, contract research, custom synthesis and custom manufacturing of intermediates and APIs.

The Hikal Advantage

Proven Expertise

Deep experience in custom synthesis, contract research, and product development, serving global innovator companies.


Strong R&D and Scale-up Capabilities

End-to-end development across the life sciences value chain, supported by lab-to-commercial scale-up capabilities and a high-potency lab at the Pune R&T centre.

Globally Compliant Operations

Operations aligned with leading global regulatory standards, with approvals from US FDA (cGMP), TGA-GMP, KFDA (Korea), PMDA (Japan), AFMPS (Belgium), EDQM, EPA, and COFEPRIS (Mexico), along with GMP-compliant animal health facilities.

Our Capabilities



Our Products

Anti-convulsant, Anti-inflammatory, Analgesic, Anti-parasitic, Anti-lipemic, Anti-histaminic, Anti-depressant, Anti-psychotic, Anti-emetic, Anti-diabetic, Anti-thrombotic, Anti-viral, Haemorheologic

Business Highlights in 2025-26

- Continued with a strong recovery trajectory, with operations normalised, customer ordering patterns stabilised and capacity utilisation improving across key facilities
- Strengthened differentiated CDMO capabilities through the operationalisation of the OEB-5 compliant HPAPI laboratory, expanded Pune R&T Centre and Panoli pilot plant, enhancing development, scale-up and technology transfer capabilities
- Progressed US FDA remediation at the Bengaluru facility, with CAPAs nearing completion, while reinforcing quality systems, manufacturing excellence and business continuity through dual-site validation
- Enhanced manufacturing efficiency at the Mahad site through automation and Value Stream Mapping, improving output with zero production downtime
- Expanded capabilities in high-value and next-generation chemistries, including HPAPIs, ADCs, PROTACs and peptide drug conjugates
- Advanced a robust pipeline of niche APIs and CDMO programmes across development, pilot and commercialisation stages, supported by increasing DMF filings and R&D focused on oncology, CNS, gastroenterology and anti-diabetic therapies
- Strengthened global customer engagement and benefited from increasing China+1 outsourcing opportunities, reinforcing our position as a preferred global CDMO partner